STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBIX
  4. [Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

Director Shalini Sharp converts 1,659 RSUs into NBIX common stock shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Shalini Sharp exercised restricted stock units into common stock. She acquired 1,659 shares of common stock from vested RSUs and did not sell any shares in this filing. Following the transaction, she directly holds 4,088 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Sharp Shalini
Role null
Type Security Shares Price Value
Exercise Restricted Stock Unit 1,659 $0.00 --
Exercise Common Stock 1,659 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock — 4,088 shares (Direct, null)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.
RSUs exercised 1,659 shares Restricted Stock Units converted into common stock
Common shares acquired 1,659 shares Common Stock received from RSU exercise
Shares held after 4,088 shares Total direct common stock ownership post-transaction
Transaction date May 21, 2026 Date of RSU exercise/conversion
RSU grant date May 21, 2025 Original grant date of fully vested RSU award
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents the right to receive one share..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sharp Shalini
(Last)(First)(Middle)
6027 EDGEWOOD BEND CT.
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/21/2026M1,659A$04,088D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0(1)05/21/2026M1,659 (2) (2)Common Stock1,659$00D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
2. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.
Remarks:
/s/ Darin Lippoldt, Attorney-in-Fact05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NBIX director Shalini Sharp report on this Form 4?

Shalini Sharp reported exercising restricted stock units into common stock. She converted 1,659 RSUs into 1,659 shares of Neurocrine Biosciences common stock, reflecting a routine compensation-related equity settlement with no open-market purchases or sales.

How many NBIX shares did Shalini Sharp acquire in this Form 4 filing?

She acquired 1,659 shares of Neurocrine Biosciences common stock. These shares came from the exercise of an equal number of restricted stock units that were fully vested, rather than from an open-market stock purchase transaction.

Did Shalini Sharp sell any NEUROCRINE BIOSCIENCES (NBIX) shares in this Form 4?

No shares were sold in this Form 4. The filing only shows an exercise of 1,659 restricted stock units into common stock, with no reported dispositions, sales, gifts, or tax-withholding share transfers associated with the transaction.

What is Shalini Sharp’s NBIX common stock holding after this transaction?

After the RSU exercise, Shalini Sharp directly holds 4,088 shares of Neurocrine Biosciences common stock. This post-transaction balance reflects her updated direct ownership position reported in the Form 4’s non-derivative securities table.

What are the key details of the restricted stock units in this NBIX Form 4?

Each restricted stock unit represents the right to receive one share of common stock upon vesting. The RSU award reported here was granted on May 21, 2025 and is fully vested, allowing conversion of 1,659 RSUs into 1,659 common shares.